drugset / Trial / NCT00646854
Alemtuzumab and CHOP in T-cell Lymphoma
Phase 3
Completed
136 enrolled
Aarhus University Hospital
GCP-unit at Aarhus University Hospital, Aarhus, Denmark · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine efficacy and safety of the monoclonal antibody MabCampath® (alemtuzumab) combined with chemotherapy in the treatment of T-cell lymphoma.
Timeline
- Start
- 2008-06
- Primary completion
- 2016-12-31
- Completion
- 2016-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 50 mg/m2 | Oral |
| Background | Vincristine | Small molecule | 1 mg/m2 | Intravenous |